Back to discover
Disease

Acute Pain

Late-stage therapeutic developmentEmerging research
MeSHAcute Pain
2
Publications
24
Clinical trials
1
Related conditions
2023
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Sickle Cell Disease: From Genetics to Curative Approaches.

Research2023-08-01Annual review of genomics and human genetics

Cellular Circuits in the Brain and Their Modulation in Acute and Chronic Pain.

Research2020-06-11Physiological reviews

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 2 clinical trials expected to report results, the earliest in Q4 2026.
  • 1 safety action from EMA issued.
  • 1 industry development reported.
Upcoming Milestones
Major developments
Major clinical milestoneImportant
Myogenous Face Pain Following Third Molar Extractions Under Intravenous Sedation
Primary completion2026-08-01
Upcoming trial readoutImportant
Examining The Effects Of Intravenous Oxytocin Infusion On Peripheral Sensory Afferents Using Microneurography Technique In Healthy Volunteers: A Triple-Blind, Randomized, Placebo-Controlled Trial
Results expected Q2 20272026-02-13
Major safety communicationImportant
Market withdrawal — Eptifibatide
Integrilin is intended for use with acetylsalicylic acid and unfractionated heparin. Integrilin is indicated for the prevention of early myocardial infarction in patients presenting with unstable angina or non-Q-wave myocardial infarction with the last episode of chest pain occurring within 24 hours and with ECG changes and / or elevated cardiac enzymes. Patients most likely to benefit from Integrilin treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early percutaneous transluminal coronary angioplasty (PTCA).2026-01-01
Clinical Milestones10View all 10
Results expected 2
Recently completed 5
+2 more in the activity timeline below
Industry & Market1View
Regulatory Updates1View
  • 2026-01-01Market withdrawal — EptifibatideIntegrilin is intended for use with acetylsalicylic acid and unfractionated heparin. Integrilin is indicated for the prevention of early myocardial infarction in patients presenting with unstable angina or non-Q-wave myocardial infarction with the last episode of chest pain occurring within 24 hours and with ECG changes and / or elevated cardiac enzymes. Patients most likely to benefit from Integrilin treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early percutaneous transluminal coronary angioplasty (PTCA).
Activity timeline12

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Sufentanil citrateapproved

Approval — Dzuveo is indicated for the management of acute moderate to severe pain in adult patients. (2018)

Eptifibatideapproved

Approval — Eptifibatide Accord is intended for use with acetylsalicylic acid and unfractionated hepa… (2016)

Clinical trials

17 sponsors · 2 new · 5 completed in the last 12 months (net +2)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
15
Late-stage
6
Completed
Late-stage studies

Intravenous Ketorolac Vs. Morphine In Children Presenting With Acute Abdominal Pain And/or Suspected Appendicitis: A Multi-centre Non-Inferiority Randomized Controlled Trial

Phase 3 · Recruiting · University of Calgary

Fentanyl or Esketamine for Traumatic PAIN (FORE-PAIN) Trial

Phase 3 · Recruiting · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Efficacy and Safety of Liposomal Bupivacaine Injection for Paravertebral Nerve Block in the Treatment of Acute and Chronic Pain After Thoracoscopic Pneumonectomy: A Multicenter, Randomized, Double-blind, Controlled Clinical Trial

Phase 4 · Recruiting · The Second Affiliated Hospital of Chongqing Medical University

Etude randomisée contrôlée en Double-aveugle ESKAPE : ESKétamine Low-dose Versus kétamine Low-dose Pour la Douleur Aiguë sévère Aux Urgences, Comparaison Des Effets PsychodyslEptiques

Phase 4 · Completed · Centre Hospitalier Universitaire de Nice

Liposomal Bupivacaine for Acute Pain Management Following Posterior Lumbar Decompression and Fusion Surgery in Adults: A Prospective, Randomized Controlled Trial

Phase 4 · Completed · Min Li

Liposomal Bupivacaine With Standard Bupivacaine Versus Dexmedetomidine With Standard Bupivacaine for Supraclavicular Brachial Plexus Block in Distal Radial Fracture Surgery: a Randomized Controlled Trial.

Phase 3 · Completed · The University of Hong Kong
Recruiting

Intravenous Ketorolac Vs. Morphine In Children Presenting With Acute Abdominal Pain And/or Suspected Appendicitis: A Multi-centre Non-Inferiority Randomized Controlled Trial

Phase 3 · Recruiting · University of Calgary

Fentanyl or Esketamine for Traumatic PAIN (FORE-PAIN) Trial

Phase 3 · Recruiting · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Efficacy and Safety of Liposomal Bupivacaine Injection for Paravertebral Nerve Block in the Treatment of Acute and Chronic Pain After Thoracoscopic Pneumonectomy: A Multicenter, Randomized, Double-blind, Controlled Clinical Trial

Phase 4 · Recruiting · The Second Affiliated Hospital of Chongqing Medical University

Examining The Effects Of Intravenous Oxytocin Infusion On Peripheral Sensory Afferents Using Microneurography Technique In Healthy Volunteers: A Triple-Blind, Randomized, Placebo-Controlled Trial

Phase 2 · Recruiting · Wake Forest University Health Sciences

Myogenous Face Pain Following Third Molar Extractions Under Intravenous Sedation

Phase 2 · Recruiting · Rutgers, The State University of New Jersey

Non-randomized Prospective Pilot Study on Effect of Temporo-masseteric Nerve Block (TMNB) on Pain Reduction Following Wisdom Molar Extractions

Phase 2 · Recruiting · Rutgers, The State University of New Jersey
Recently completed

Etude randomisée contrôlée en Double-aveugle ESKAPE : ESKétamine Low-dose Versus kétamine Low-dose Pour la Douleur Aiguë sévère Aux Urgences, Comparaison Des Effets PsychodyslEptiques

Phase 4 · Completed · Centre Hospitalier Universitaire de Nice

Liposomal Bupivacaine for Acute Pain Management Following Posterior Lumbar Decompression and Fusion Surgery in Adults: A Prospective, Randomized Controlled Trial

Phase 4 · Completed · Min Li

Liposomal Bupivacaine With Standard Bupivacaine Versus Dexmedetomidine With Standard Bupivacaine for Supraclavicular Brachial Plexus Block in Distal Radial Fracture Surgery: a Randomized Controlled Trial.

Phase 3 · Completed · The University of Hong Kong

A Phase 4, Open-label, Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine As Part of Multimodal Therapy for Acute Pain After Laparoscopic Procedures of the Intraperitoneal or Retroperitoneal Cavities or Arthroscopic Orthopedic Procedures

Phase 4 · Completed · Vertex Pharmaceuticals Incorporated

Erector Spinae Plane Block Versus Intertransverse Process Block: a Randomized Control Trial in Healthy Volunteers

Phase 4 · Completed · Duke University

Intranasal Ketamine Versus Subcutaneous Ketamine for Treatment of Post Traumatic Acute Pain in the Emergency Department

Phase 2/3 · Completed · University of Monastir

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2018emaApproval — Sufentanil citrate· Dzuveo is indicated for the management of acute moderate to severe pain in adult patients. source ↗
2016emaApproval — Eptifibatide· Eptifibatide Accord is intended for use with acetylsalicylic acid and unfractionated heparin. Eptifibatide Accord is indicated for the prevention of early myocardial infarction in adults presenting with unstable angina or non-Q-wave myocardial infarction, with the last episode of chest pain occurring within 24 hours and with electrocardiogram (ECG) changes and/or elevated cardiac enzymes. Patients most likely to benefit from Eptifibatide Accord treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early PTCA (Percutaneous Transluminal Coronary Angioplasty). source ↗
Safety updates
2026emaMarket withdrawal — Eptifibatide· Integrilin is intended for use with acetylsalicylic acid and unfractionated heparin. Integrilin is indicated for the prevention of early myocardial infarction in patients presenting with unstable angina or non-Q-wave myocardial infarction with the last episode of chest pain occurring within 24 hours and with ECG changes and / or elevated cardiac enzymes. Patients most likely to benefit from Integrilin treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early percutaneous transluminal coronary angioplasty (PTCA). source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20212023
Most influential

Cellular Circuits in the Brain and Their Modulation in Acute and Chronic Pain.

Physiological reviews · 2021 · 238 cites

Sickle Cell Disease: From Genetics to Curative Approaches.

Annual review of genomics and human genetics · 2023 · 18 cites
Recent publications

Sickle Cell Disease: From Genetics to Curative Approaches.

Annual review of genomics and human genetics · 2023 · 18 cites

Cellular Circuits in the Brain and Their Modulation in Acute and Chronic Pain.

Physiological reviews · 2021 · 238 cites
Major themes4
  • Acute Pain1
  • Anemia, Sickle Cell1
  • Chronic Pain1
  • Hemoglobins, Abnormal1
Leading journals2
  • Annual review of genomics and human genetics1
  • Physiological reviews1
Leading researchers8
  • Cavazzana M1
  • Corsia A1
  • Hardouin G1
  • Kuner R1
  • Kuner T1
  • Magrin E1
  • Miccio A1
  • Semeraro M1
Affiliations (unnormalised)6
  • Centre d'Investigation Clinique and Unité de Recherche Clinique1
  • Centre d'Investigation Clinique Spécialisé en Biothérapie1
  • Human Lymphohematopoiesis Laboratory1
  • Imagine Institute1
  • Institute of Pharmacology1
  • Laboratory of Chromatin and Gene Regulation During Development1

Related conditions

1 match

Diseases frequently studied alongside this one. Number shows shared papers.

Chronic Pain2

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Intensely discomforting, distressful, or agonizing sensation associated with trauma or disease, with well-defined location, character, and timing.

Identifiers
MeSHAcute Pain
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.